Literature DB >> 14682604

Results of lung volume reduction surgery for emphysema.

Douglas E Wood1.   

Abstract

LVRS provides an exciting opportunity for palliation of symptoms and improvement in quality of life for patients who have severe end-stage emphysema. Because no medical therapy has been able to improve pulmonary function or reverse the inexorable decline of breathless patients who have emphysema, this opportunity to improve lung function and quality of life is one of the most innovative additions to thoracic surgery since the first successful lung transplant procedure 20 years ago. Although initial short-term, case-controlled surgeries were criticized because of incomplete and short follow-up care, substantial long-term data now exist to support the use of LVRS for select patients who have severe emphysema. Patients who have upper lobe predominant disease or low exercise capacity are more likely to have a benefit in exercise capacity and quality of life after LVRS. Selected patients who have upper lobe emphysema and poor exercise capacity are also more likely to have improved survival after LVRS. The individual contributions by the large number of investigators pioneering LVRS development, along with the collective contributions of the NETT investigators, have propelled the knowledge surrounding LVRS far beyond that of any similar new technology or procedure in its adolescence.

Entities:  

Mesh:

Year:  2003        PMID: 14682604     DOI: 10.1016/s1052-3359(03)00100-5

Source DB:  PubMed          Journal:  Chest Surg Clin N Am        ISSN: 1052-3359


  2 in total

Review 1.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

2.  The Efficacy of Lung Volume Reduction Coil Treatment in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) Type II Respiratory Failure.

Authors:  Fidan Yildiz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.